DPx Holdings B.V., privately owned by JLL Partners and Royal DSM and the parent company of Patheon, has completed the transaction to acquire Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics. Patheon's biologic drug substance business, a unit of DPx Holdings, now includes four global facilities in Europe, Australia, and North America and more than 550 employees.

The two existing Gallus sites in St. Louis, Missouri and Princeton, New Jersey are the first Patheon biologic drug substance sites in the US and complement Patheon’s  two existing sites in Groningen, the Netherlands and Brisbane, Australia. Three of these four global sites each have nearly three decades of mammalian cell culture experience while the fourth site in Brisbane was opened within the last year. 

Source: Patheon